

## Co-enrolment List

Co-enrolment of patients into the HOT-COVID trial and the following clinical trials is accepted by relevant steering committees

| <b>Title of trial</b>   |
|---|
| Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)   |
| Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy (iTACTIC).  |
| Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial (VIPER-SHOCK)   |
| Agents Intervening against Delirium in the Intensive Care Unit (AID-ICU)  |
| Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest (VAM-IHCA)  |
| The Conservative vs. Liberal Approach to fluid therapy of Septic Shock in Intensive Care (CLASSIC) Trial                              |
| Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest (TAME)  |
| Biomarker-guided Duration of Antibiotic treatment in hospitalised Patients with suspected Sepsis: the ADAPT-Sepsis Trial              |
| Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure (COMBAT-SHINE) |
| PROCalcitonin-based algorithm for antibiotic use in Acute Pancreatitis (PROCAP)   |

|   |
|---|
| A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation (CRYOSTAT-2)         |
| Clinical Evaluation of a Point of Care (POC) assay to identify PPhenotypes IN the Acute Respiratory Distress Syndrome (PHIND trial)   |
| Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)  |
| Low dose hydrocortisone in patients with COVID-19 and severe hypoxia – the COVID STEROID Trial  |
| Goal directed fluid removal with furosemide in intensive care patients with fluid overload – A randomised, blinded, placebo-controlled trial (GODIF)  |
| Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial   |
| Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial (COVIPOC)   |
| Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform (CCAP-RCT / CCAP-2) |
| Recombinant Human   |

Alkaline Phosphatase SA-AKI Survival  
Trial (REVIVAL)